Lasa Supergenerics First Quarter 2026 Earnings: ₹4.22 loss per share (vs ₹0.55 loss in 1Q 2025)
Lasa Supergenerics (NSE:LASA) First Quarter 2026 Results
Key Financial Results
- Revenue: ₹201.5m (down 35% from 1Q 2025).
- Net loss: ₹211.2m (loss widened by ₹183.9m from 1Q 2025).
- ₹4.22 loss per share (further deteriorated from ₹0.55 loss in 1Q 2025).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Lasa Supergenerics shares are down 11% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 4 warning signs for Lasa Supergenerics you should know about.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NSEI:LASA
Lasa Supergenerics
Engages in the research, manufacture, and marketing of animal and human healthcare products in India.
Adequate balance sheet with slight risk.
Market Insights
Community Narratives

